Combination Therapy with Tenofovir DisoproxilFumarate/Emtricitabine/Elvitegravir/Cobicistat Plus Darunavir Once Daily inAntiretroviral-Naive and Treatment-Experienced Patients: A RetrospectiveReview

摘要

Background:Patients with drug-resistant HIV often require complex antiretroviral regimens. However, combining fixed-dose combination tablets such as tenofovir–disoproxil–fumarate, emtricitabine, and cobicistat-boosted elvitegravir (TDF/FTC/EVG/cobi) with darunavir (DRV) can provide a simple, once-daily (QD), 2-tablet regimen for patients with drug-resistant HIV. Primary objective was to determine the percentage of patients with HIV-1 RNA <40 copies/mL at 48 weeks.